Huang and colleagues22 described a case of an EGFRdel19/T790M + NSCLC patient who developed BRAF V600E-driven AR after second-line osimertinib and achieved stable disease under dabrafenib 150 mg BID, trametinib 1 mg OD and osimertinib 80 mg OD, with ongoing disease control 7.4 months after. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.